ArticleFrontiers in immunology2026
Early on-treatment dynamics predicting hepatitis B e antigen seroconversion in chronic hepatitis B.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B e antigen (HBeAg) loss with anti-HBe appearance marks the first durable immunological milestone during nucleos(t)ide analogues (NAs) therapy, yet static baseline or single time-point biomarkers anticipate this event poorly. We hypothesized that early dynamic parameters reflecting viral, antigenic and hepatic function during the first 12 weeks of therapy contain richer prognostic information than baseline values alone. Aims: This study aimed to construct a model that fuses week-12 changes in serum biochemical and virological parameters and tested its performance in predicting week-60 HBeAg seroconversion (SR). Methods: Serum biochemical and virological parameters of HBeAg-positive patients receiving NAs treatment between January and December 2023 were collected. Difference, ratio and absolute week-12 values of variables were derived. After ten-fold cross-validation, a multi-variable signature was selected to build a least absolute shrinkage and selection operator (LASSO) logistic regression model. Results: Overall, 38.24% (26/68) of patients achieved HBeAg SR. Using LASSO regression with ten-fold cross-validation, an eight-variable signature related to the dynamic changes of HBeAg, hepatitis B surface antigen (HBsAg), gamma-glutamyl transferase (GGT), and albumin (ALB) were selected. In the training cohort (n=68), the multi- variable model demonstrated an area under the curve (AUC) of 0.975 (sensitivity, 96.2%; specificity, 95.2%), significantly outperforming single-variable models. In the test cohort (n=34), the model achieved an AUC of 0.721 with maintained high specificity (95%) and positive predictive value (PPV, 90%). Conclusions: Early on-treatment integrated dynamics of HBeAg, HBsAg, GGT and ALB showed predictive value for subsequent HBeAg SR. The eight-variable model may assist monitoring or alternative strategies in patients receiving treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.